---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-007831"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:53:55.354346+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# MAIA Biotechnology updates on Phase 3 ateganosine trial in NSCLC; Fast Track status

## Summary
- Ongoing Phase 3 full approval trial of ateganosine for third-line non-small cell lung cancer.
- FDA Fast Track designation provides clear regulatory pathway for ateganosine.
- First and only direct telomere-targeting anticancer agent in clinical development.
- Targets ~50,000 US patients annually in 3L NSCLC with no established standard of care.
- CEO Vlad Vitoc cites $50 billion global immunotherapy market opportunity in letter.

## SEC filing metadata
- accession: 0001493152-26-007831
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000149315226007831/0001493152-26-007831-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000149315226007831/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-007831
- JSON: https://secwatch.observer/filing/0001493152-26-007831.json
- Plain text: https://secwatch.observer/filing/0001493152-26-007831.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.